脊髓损伤(SCI)治疗的新基因治疗技术:有效的直接谱系重编程

Q4 Medicine

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Pub Date : 2022-10-03 DOI:10.33597/jcpt-03-id1028

Chunggoo Kim, Hyun Soo Shim, Yujung Chang, Hyeonjoo Im, Junsang Yoo

{"title":"脊髓损伤(SCI)治疗的新基因治疗技术:有效的直接谱系重编程","authors":"Chunggoo Kim, Hyun Soo Shim, Yujung Chang, Hyeonjoo Im, Junsang Yoo","doi":"10.33597/jcpt-03-id1028","DOIUrl":null,"url":null,"abstract":"What is known and objectives: Spinal Cord Injury (SCI) is defined for the last few decades as patients getting wheelchair bound and under medication for a lifetime [1]. Medical battery for SCI is very limited which often results in heightened frustration for the caregivers who land up with no solid solution to the condition. However, in recent times due to the huge volume of research, neuroscience has progressed massively through GT offering better insight and high hopes of neural regeneration and functional rehabilitation [2]. As GT technology becomes more popular as an emerging therapeutic method, many studies using a manufactured virus (AAV, retro, adeno, lenti) are opening up promising research avenues [3-5]. In this review, we dealt with Direct Lineage Reprogramming (DLR) technology for a novel GT method for SCI patients.","PeriodicalId":14602,"journal":{"name":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","volume":"18 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Novel Gene Therapies Technology for Spinal Cord Injury (SCI) Therapy: Efficient Direct Lineage Reprogramming\",\"authors\":\"Chunggoo Kim, Hyun Soo Shim, Yujung Chang, Hyeonjoo Im, Junsang Yoo\",\"doi\":\"10.33597/jcpt-03-id1028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"What is known and objectives: Spinal Cord Injury (SCI) is defined for the last few decades as patients getting wheelchair bound and under medication for a lifetime [1]. Medical battery for SCI is very limited which often results in heightened frustration for the caregivers who land up with no solid solution to the condition. However, in recent times due to the huge volume of research, neuroscience has progressed massively through GT offering better insight and high hopes of neural regeneration and functional rehabilitation [2]. As GT technology becomes more popular as an emerging therapeutic method, many studies using a manufactured virus (AAV, retro, adeno, lenti) are opening up promising research avenues [3-5]. In this review, we dealt with Direct Lineage Reprogramming (DLR) technology for a novel GT method for SCI patients.\",\"PeriodicalId\":14602,\"journal\":{\"name\":\"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS\",\"volume\":\"18 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33597/jcpt-03-id1028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33597/jcpt-03-id1028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

摘要

已知情况和目标:在过去的几十年里，脊髓损伤(SCI)被定义为患者被轮椅束缚并终生接受药物治疗[1]。对于脊髓损伤的医疗电池是非常有限的，这通常会导致护理人员在没有坚实的解决方案的情况下感到非常沮丧。然而，近年来由于大量的研究，神经科学通过GT取得了巨大的进展，为神经再生和功能康复提供了更好的见解和更高的希望[2]。随着GT技术作为一种新兴的治疗方法越来越受欢迎，许多使用人造病毒(AAV、retro、adeno、lenti)的研究正在开辟有前途的研究途径[3-5]。在这篇综述中，我们讨论了直接谱系重编程(Direct Lineage Reprogramming, DLR)技术作为一种治疗SCI患者的新型GT方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel Gene Therapies Technology for Spinal Cord Injury (SCI) Therapy: Efficient Direct Lineage Reprogramming

What is known and objectives: Spinal Cord Injury (SCI) is defined for the last few decades as patients getting wheelchair bound and under medication for a lifetime [1]. Medical battery for SCI is very limited which often results in heightened frustration for the caregivers who land up with no solid solution to the condition. However, in recent times due to the huge volume of research, neuroscience has progressed massively through GT offering better insight and high hopes of neural regeneration and functional rehabilitation [2]. As GT technology becomes more popular as an emerging therapeutic method, many studies using a manufactured virus (AAV, retro, adeno, lenti) are opening up promising research avenues [3-5]. In this review, we dealt with Direct Lineage Reprogramming (DLR) technology for a novel GT method for SCI patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS Medicine-Pharmacology (medical)

CiteScore

0.20

自引率

0.00%

发文量